Core Viewpoint - The announcement indicates that the company's wholly-owned subsidiary, Shandong Huabo Kaisheng Biotechnology Co., Ltd., has participated in the 11th batch of national centralized drug procurement and is expected to be selected for the procurement of specific pharmaceutical products [1] Group 1: Company Participation - Shandong Huabo Kaisheng Biotechnology Co., Ltd. participated in the 11th batch of national drug centralized procurement bidding [1] - The company’s products are listed in the public announcement of the proposed selection results by the National Organization for Drug Joint Procurement Office [1] Group 2: Selected Products - The product Fumaric Acid Luppatadine Tablets, suitable for the symptomatic treatment of allergic rhinitis and urticaria in adults and adolescents (12 years and older), has a proposed selection price of 30.49 yuan per box, with a specification of 10mg and packaging of 28 tablets per box [1] - The product Alendronate Sodium Tablets, used for the treatment of osteoporosis to prevent hip and spinal fractures, has a proposed selection price of 6.2 yuan per box, with a specification of 70mg and packaging of 4 tablets per box [1]
泰恩康：全资子公司华铂凯盛拟中标国家药品集中采购